Efficacy of IL12/23 Blockade Expands Our Therapeutic Targets and Challenges the Old Dogma in Ulcerative Colitis
- PMID: 32199882
- PMCID: PMC8576588
- DOI: 10.1053/j.gastro.2020.03.024
Efficacy of IL12/23 Blockade Expands Our Therapeutic Targets and Challenges the Old Dogma in Ulcerative Colitis
Comment on
-
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750. N Engl J Med. 2019. PMID: 31553833 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
